| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Luciano De Petrocellis, Vincenzo Di Marz. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 5. issue 1. 2010-05-11. PMID:19847654. |
the molecular mechanism of action of delta(9)-tetrahydrocannabinol (thc), the psychotropic constituent of cannabis, has been a puzzle during the three decades separating its characterization, in 1964, and the cloning, in the 1990s, of cannabinoid cb1 and cb2 receptors. |
2010-05-11 |
2023-08-12 |
Not clear |
| Luciano De Petrocellis, Vincenzo Di Marz. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 5. issue 1. 2010-05-11. PMID:19847654. |
however, while these latter proteins do mediate most of the pharmacological actions of thc, they do not seem to act as receptors for other plant cannabinoids (phytocannabinoids), nor are they the unique targets of the endogenous lipids that were originally identified in animals as agonists of cb1 and cb2 receptors, and named endocannabinoids. |
2010-05-11 |
2023-08-12 |
Not clear |
| Elisa Torres, Maria Dolores Gutierrez-Lopez, Erika Borcel, Ines Peraile, Andrea Mayado, Esther O'Shea, Maria Isabel Colad. Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain. Journal of neurochemistry. vol 113. issue 1. 2010-04-30. PMID:20067581. |
evidence that mdma ('ecstasy') increases cannabinoid cb2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain. |
2010-04-30 |
2023-08-12 |
rat |
| Elisa Torres, Maria Dolores Gutierrez-Lopez, Erika Borcel, Ines Peraile, Andrea Mayado, Esther O'Shea, Maria Isabel Colad. Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain. Journal of neurochemistry. vol 113. issue 1. 2010-04-30. PMID:20067581. |
over-expression of the cannabinoid cb2 receptor in microglia during non-immune and immune pathological conditions is thought to be aimed at controlling the production of neurotoxic factors such as proinflammatory cytokines. |
2010-04-30 |
2023-08-12 |
rat |
| Orazio Mazzoni, Maria V Diurno, Antonio M di Bosco, Ettore Novellino, Paolo Grieco, Giovanni Esposito, Alessia Bertamino, Antonio Calignano, Roberto Russ. Synthesis and pharmacological evaluation of analogs of indole-based cannabimimetic agents. Chemical biology & drug design. vol 75. issue 1. 2010-04-27. PMID:19895505. |
with the aim of investigating the structure-activity relationships (sar) for the binding of non-classical agonists to cb1 and cb2 cannabinoid receptors, we designed and synthesized a series of indole derivatives. |
2010-04-27 |
2023-08-12 |
Not clear |
| Shuxian Jiang, Yigong Fu, John Williams, Jodianne Wood, Lakshmipathi Pandarinathan, Shiri Avraham, Alexandros Makriyannis, Shalom Avraham, Hava Karsenty Avraha. Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. PloS one. vol 2. issue 7. 2010-04-23. PMID:17653268. |
expression and function of cannabinoid receptors cb1 and cb2 and their cognate cannabinoid ligands in murine embryonic stem cells. |
2010-04-23 |
2023-08-12 |
Not clear |
| David A Price, Alex A Martinez, Alexandre Seillier, Wouter Koek, Yolanda Acosta, Elizabeth Fernandez, Randy Strong, Beat Lutz, Giovanni Marsicano, James L Roberts, Andrea Giuffrid. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. The European journal of neuroscience. vol 29. issue 11. 2010-04-19. PMID:19490092. |
at 3 days post-mptp, we found significant microglial activation and up-regulation of cb2 cannabinoid receptors in the ventral midbrain. |
2010-04-19 |
2023-08-12 |
mouse |
| David A Price, Alex A Martinez, Alexandre Seillier, Wouter Koek, Yolanda Acosta, Elizabeth Fernandez, Randy Strong, Beat Lutz, Giovanni Marsicano, James L Roberts, Andrea Giuffrid. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. The European journal of neuroscience. vol 29. issue 11. 2010-04-19. PMID:19490092. |
in conclusion, our data indicate that agonism at cb2 cannabinoid receptors protects against mptp-induced nigrostriatal degeneration by inhibiting microglial activation/infiltration and suggest that cb2 receptors represent a new therapeutic target to slow the degenerative process occurring in pd. |
2010-04-19 |
2023-08-12 |
mouse |
| Maurizio Guida, Alessia Ligresti, Daniele De Filippis, Alessandra D'Amico, Stefania Petrosino, Mariateresa Cipriano, Giuseppe Bifulco, Sara Simonetti, Pierangelo Orlando, Luigi Insabato, Carmine Nappi, Attilio Di Spiezio Sardo, Vincenzo Di Marzo, Teresa Iuvon. The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. Endocrinology. vol 151. issue 3. 2010-03-26. PMID:20133454. |
the levels of the endocannabinoid receptor cb2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. |
2010-03-26 |
2023-08-12 |
human |
| Stefania Petrosino, Vincenzo Di Marz. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Current opinion in investigational drugs (London, England : 2000). vol 11. issue 1. 2010-03-23. PMID:20047159. |
following the identification of receptors for thc - the cannabinoid cb1 and cb2 receptors - in mammals, various pharmaceutical strategies have attempted to exploit the properties of the cannabinoid system while minimizing psychotropic side effects. |
2010-03-23 |
2023-08-12 |
Not clear |
| Stefania Petrosino, Vincenzo Di Marz. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Current opinion in investigational drugs (London, England : 2000). vol 11. issue 1. 2010-03-23. PMID:20047159. |
the cloning of the cannabinoid cb1 and cb2 receptors enabled the discovery of the endogenous agonists of the receptors, the endocannabinoids, and eventually led to the identification of enzymes that catalyze endocannabinoid inactivation. |
2010-03-23 |
2023-08-12 |
Not clear |
| Diego Centonze, Francesco Mori, Giacomo Koch, Fabio Buttari, Claudia Codecà, Silvia Rossi, Maria Teresa Cencioni, Monica Bari, Stefania Fiore, Giorgio Bernardi, Luca Battistini, Mauro Maccarron. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 30. issue 6. 2010-03-22. PMID:19768368. |
this compound also failed to affect the synthesis and the degradation of the endocannabinoid anandamide, as well as the expression of both cb1 and cb2 cannabinoid receptors in various subpopulations of peripheral lymphocytes. |
2010-03-22 |
2023-08-12 |
Not clear |
| Itai Bab, Andreas Zimmer, Eitan Melame. Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Annals of medicine. vol 41. issue 8. 2010-03-09. PMID:19634029. |
the active component of marijuana, delta(9)-tetrahydrocannabinol, activates the cb1 and cb2 cannabinoid receptors, thus mimicking the action of endogenous cannabinoids. |
2010-03-09 |
2023-08-12 |
mouse |
| S Jayanthi, S Buie, S Moore, R I Herning, W Better, N M Wilson, C Contoreggi, J L Cade. Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses. Molecular psychiatry. vol 15. issue 1. 2010-03-02. PMID:18475272. |
marijuana-induced increases in apoc-iii levels might occur through chronic stimulation of hepatic cannabinoid receptors (cb1 and/or cb2) by its active ingredient, delta(9)tetrahydrocannibol (thc). |
2010-03-02 |
2023-08-12 |
Not clear |
| Bradley K Taylo. Spinal inhibitory neurotransmission in neuropathic pain. Current pain and headache reports. vol 13. issue 3. 2010-03-01. PMID:19457281. |
these include numerous g protein-coupled receptors (mu- and delta-opioid, alpha(2)-adrenergic, purinergic a1, neuropeptide y1 and y2, cannabinoid cb1 and cb2, muscarinic m2, gamma-amino-butyric acid type b, metabotropic glutamate type ii-iii, somatostatin) and perhaps nuclear receptors (peroxisome proliferator-activated receptor gamma). |
2010-03-01 |
2023-08-12 |
Not clear |
| Ki Hoon Han, Sunny Lim, Jewon Ryu, Cheol-Whan Lee, Yuna Kim, Ju-Hee Kang, Soon-Suk Kang, Yeong Ki Ahn, Chan-Sik Park, Jae Joong Ki. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovascular research. vol 84. issue 3. 2010-02-24. PMID:19596672. |
cb1 and cb2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. |
2010-02-24 |
2023-08-12 |
Not clear |
| Ki Hoon Han, Sunny Lim, Jewon Ryu, Cheol-Whan Lee, Yuna Kim, Ju-Hee Kang, Soon-Suk Kang, Yeong Ki Ahn, Chan-Sik Park, Jae Joong Ki. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovascular research. vol 84. issue 3. 2010-02-24. PMID:19596672. |
we investigated the mechanism by which cannabinoid receptors-1 (cb1) and -2 (cb2) modulate inflammatory activities of macrophages. |
2010-02-24 |
2023-08-12 |
Not clear |
| L Luongo, E Palazzo, S Tambaro, C Giordano, L Gatta, M A Scafuro, F Sca Rossi, P Lazzari, L Pani, V de Novellis, M Malcangio, S Maion. 1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiology of disease. vol 37. issue 1. 2010-02-22. PMID:19804829. |
here, we have investigated the effect of chronic treatment with a selective agonist of cannabinoid type 2 receptor (cb2), 1-(2',4'-dichlorophenyl)-6-methyl-n-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3 carboxamide (ness400), on pain thresholds in the spared nerve injury (sni) model in the mouse and on the distribution and activation of spinal microglia. |
2010-02-22 |
2023-08-12 |
mouse |
| Bruno M Fonseca, Georgina Correia-da-Silva, Anthony H Taylor, Justin C Konje, Stephen C Bell, Natércia A Teixeir. Spatio-temporal expression patterns of anandamide-binding receptors in rat implantation sites: evidence for a role of the endocannabinoid system during the period of placental development. Reproductive biology and endocrinology : RB&E. vol 7. 2010-02-15. PMID:19860893. |
since high anandamide (aea) levels, the main endocannabinoid, are detrimental to implantation and in order to gain insight into the role of the endocannabinoid system in the development of the fetoplacental unit, the spatio-temporal pattern of expression of the anandamide-binding receptors, cb1, cb2 and the vanilloid receptor (trpv1), were investigated by quantitative rt-pcr, western blot and immunohistochemistry. |
2010-02-15 |
2023-08-12 |
rat |
| Ewa Kozela, Maciej Pietr, Ana Juknat, Neta Rimmerman, Rivka Levy, Zvi Voge. Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. The Journal of biological chemistry. vol 285. issue 3. 2010-02-08. PMID:19910459. |
the cannabinoid anti-inflammatory action does not seem to involve the cb1 and cb2 cannabinoid receptors or the abn-cbd-sensitive receptors. |
2010-02-08 |
2023-08-12 |
mouse |